Stephannie Legarretta
Gerontology · Horizon City, TXNPI 1801537790
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 40.2% of the total. 2025 is the largest year on record at $2,510, 8.0 times the $313 reported in 2022. Among gerontology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$727
- UCB, Inc.$603
- Amgen$483
- Novartis$366
- Pfizer$363
- plus $1K from 17 others
What the payments were for
- Travel & lodging$110%
- Food & beverage$6,684100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 127 | $2,697 |
| AstraZeneca(2 entities) | 20 | $727 |
| UCB, Inc. | 18 | $603 |
| Amgen | 28 | $483 |
| Novartis | 16 | $366 |
| Pfizer | 15 | $363 |
| GSK | 8 | $338 |
| Mylan Specialty L.p. | 5 | $186 |
| Aurinia Pharma U.S., Inc. | 4 | $135 |
| Boehringer Ingelheim | 6 | $131 |
| E.r. Squibb & Sons, L.L.C. | 7 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $118 |
| Lilly USA, LLC | 2 | $102 |
| Organon | 4 | $100 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Radius Health, Inc. | 2 | $36 |
| Johnson & Johnson | 1 | $34 |
| Bayer | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Sanofi | 1 | $20 |
| Tonix Medicines, Inc. | 1 | $18 |
| Madrigal Pharmaceuticals | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,703 in reported general payments places this provider in the 95th percentile of 653 gerontology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 137 | $1,225,045 |
| RinvoqUpadacitinib | 122 | $762,478 |
| Humira(Cf)Adalimumab | 54 | $490,362 |
| Enbrel SureclickEtanercept | 30 | $221,869 |
| Xeljanz XrTofacitinib Citrate | 38 | $216,290 |
| EnbrelEtanercept | 22 | $180,150 |
| Orencia ClickjectAbatacept | 31 | $173,702 |
| Enbrel MiniEtanercept | 19 | $140,585 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 22 | $121,710 |
| Cimzia (2 Pack)Certolizumab Pegol | 15 | $92,336 |
| ProliaDenosumab | 26 | $44,041 |
| TymlosAbaloparatide | 15 | $40,445 |
| Hydroxychloroquine Sulfate | 548 | $20,743 |
| Diclofenac Sodium | 81 | $15,041 |
| Mycophenolate Mofetil | 66 | $8,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $2,697 | $1,252,840176 claims |
| AmgenEnbrel, Prolia | $483 | $224,19148 claims |
| UCB, Inc.Cimzia (2 Pack) | $603 | $92,33615 claims |
| Radius Health, Inc.Tymlos | $36 | $40,44515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 gerontology providers in Texas.
Other gerontology in Horizon City
- Kimberly WelchCoppell$113K
- Tiffany KesslerDallas$84K
- Jennifer WestFort Worth$67K
- Bailey EstesAbilene$34K
- Scott ZelaHouston$28K
- Marissa Marti-SmithDallas$27K
- Andrew BargerAustin$22K
- Meagan ChavarriaHouston$21K
- Samantha BoggsGalveston$15K
- Amber ArmstrongAustin$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.